SCHEMBL4339480

SCHEMBL4339480

Nc1onc(-c2ccc(Cl)cc2F)c1-c1ccncc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.57
MLYCD O95822 1/20 0.46
BCHE P06276 1/20 0.43
HSP90AA1 P07900 1/20 0.41
MAPK9 P45984 2/20 0.40
MAPK10 P53779 2/20 0.40
MAPK11 Q15759 1/20 0.40
RAB9A P51151 2/20 0.39
DUSP3 P51452 1/20 0.39
PTPN11 Q06124 1/20 0.39
PTGS1 P23219 1/20 0.39
SRC P12931 2/20 0.38
BRAF P15056 2/20 0.38
KDR P35968 2/20 0.38
RIPK2 O43353 1/20 0.38
EGFR P00533 1/20 0.38
TNK2 Q07912 1/20 0.38
PTK6 Q13882 1/20 0.38
MINK1 Q8N4C8 1/20 0.38
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1875685 0.84 MAPK14 (0.58) MAPK14MAPK9MAPK10MAPK11RAB9A
SCHEMBL4332772 0.83 MAPK14 (0.62) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4335175 0.82 MAPK14 (0.61) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4341519 0.82 MLYCD (0.56) MAPK14MLYCDMAPK9MAPK10MAPK11
SCHEMBL4332804 0.82 MAPK14 (0.64) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4342202 0.81 MAPK14 (0.53) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4329365 0.80 MAPK14 (0.66) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4335463 0.79 MAPK14 (0.57) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4336972 0.79 MAPK14 (0.63) MAPK14MLYCDHSP90AA1MAPK9MAPK10
SCHEMBL4342443 0.78 MAPK14 (0.71) MAPK14MLYCDMAPK9MAPK10MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036905-B1 PYRIDYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2012-12-12 EP disclosed
CN-101472921-B Pyridylisoxazole derivative ASKA PHARM CO LTD 2012-10-10 CN disclosed
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
CN-101472921-A Pyridylisoxazole derivative ASKA PHARM CO LTD (JP) 2009-07-01 CN disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885MLYCD 4475/4885BCHE 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.